James Whale Fund for Kidney Cancer is the UK’s leading specialist kidney cancer charity. It seeks to reduce the harm caused by kidney cancer by increasing knowledge and awareness, providing patient information and by supporting research into the causes, prevention and treatment of the disease.

James Whale Fund for Kidney Cancer Welcomes NICE Recommendation of axitinib

James Whale Fund for Kidney Cancer welcomes the news today that The National Institute for Health and Care Excellence (NICE) are recommending axitinib (Inlyta®) for the second line treatment of people with advanced renal cell carcinoma (RCC) after first line treatment with a tyrosine kinase inhibitor or a cytokine either fails or is not tolerated.

This recommendation comes after an earlier negative decision by NICE, which was appealed by the manufacturer of Inlyta®, Pfizer, the Royal College of Physicians, James Whale Fund for Kidney Cancer and Kidney Cancer UK.

Read Full Press Release